Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Glibenclamide oral dans l'hyperglycémie prématurée (GALOP) (GALOP)

1 octobre 2026 mis à jour par: Assistance Publique - Hôpitaux de Paris

The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Aperçu de l'étude

Description détaillée

Transient hyperglycemia of premature newborns results from an overall decrease in insulin sensitivity, which is responsible at the beta cell level for abnormalities of intragranular cleavage of proinsulin into insulin, leading to reduced active insulin secretion. Intravenous administration of exogenous insulin can be used to combat insulin resistance and lower blood glucose, but it is difficult to manage in premature newborns and is associated with a substantial risk of hypoglycemia. Glibenclamide, which stimulates endogenous insulin secretion and can be administered orally, might be an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Type d'étude

Interventionnel

Inscription (Réel)

35

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Paris, France, 75015
        • Hopital Necker - Enfants malades

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

Pas plus vieux que 7 mois (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Newborn less than 34 week of amenorrhea corrected age
  • Birth weight < 1500 g
  • Birth term < 32 week of amenorrhea
  • Hyperglycemia ≥ 10 mmol/l in 2 measurements, 3 hours apart after potential reduction of glucose intakes following each department's protocol
  • Secure venous access point (umbilical venous catheter or epicutaneo-cava catheter)
  • Enteral feeding considered before inclusion or already established
  • Consent obtained from persons holding parental authority
  • Beneficiary of social security

Exclusion Criteria

  • Contraindication to enteral feeding (at the discretion of the clinician responsible for the child)
  • Contraindication to glibenclamide according to current SPC
  • Foetal growth restriction (FGR) birth weight < 3rd percentile (AUDIPOG definition)
  • Severe birth defect, including cardiac malformation associated with a risk of myocardial ischemia
  • Severe sepsis requiring mechanical ventilation or haemodynamic support
  • Severe renal dysfunction (serum creatinine > 120 µmol/l)
  • Severe hepatocellular failure (V factor less than the standard laboratory range for the age) and/or severe cholestasis (> 50 µmol/L)
  • Hyperglycemia associated with an error in administering glucose infusion
  • Profound hypophosphoremia (< 1 mmol/l)
  • Hypersensitivity to glibenclamide or other sulphonylureas or sulphonamides, or one of the excipients
  • Patient with continuous insulin IV administration
  • Patient treated with miconazole

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Glibenclamide oral

Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk

Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk

  • For the first 10 patients during the test phase, four 0.2 ml samples will be taken at H3, H6, H10, and H24 (+/- 1 hour) after the first dose; an additional sample will be taken for patients whose blood sugar levels stabilize beyond 24 hours, after 6 hours of stable blood sugar levels (4-10 mmol/l);
  • For subsequent patients included during phase II:
  • 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment.
  • 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment
  • 1 sample of 0.2 ml per day at each daily check-up as part of care during the treatment period.
  • In centers that are unable to perform the samples and the appropriate techniques for centralizing these PK points, these samples will not be taken.

PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution.

blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized

If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.

Transaminases and hemostasis will be done only in case of clinical indication before the first administration.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Blood glucose control
Délai: At 72 hours after the first administration

The primary evaluation criteria is 72 hours blood glucose control on glibenclamide treatment (success of the treatment). This is defined as the non-use of insulin and absence of severe hypoglycemia (< 1.5 mmol/l) or persistent moderate hypoglycemia (< 2.6 mmol/l in 2 successive measurements (dextro) at an interval of more than 3 hours)

At 72 hours after the first administration

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall success of the treatment
Délai: At 36 week of amenorrhea corrected age

Overall success of the treatment defined by continuation to the end of treatment without recourse to insulin.

At 36 week of amenorrhea corrected age
Blood glucose profile on glibenclamide
Délai: At the end of treatment assessed up to 15 days

Time between the start of glibenclamide treatment and the 1st blood glucose < 10 mmol/l

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Délai: At the end of treatment assessed up to 15 days

Time between the start of glibenclamide treatment and the 1st blood glucose < 8 mmol/l

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Délai: At the end of treatment assessed up to 15 days

Proportion of time spent within the target blood glucose range (≥ 4 and < 10 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Délai: At the end of treatment assessed up to 15 days

Proportion of time spent above the target level (≥ 10 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Délai: At the end of treatment assessed up to 15 days

Proportion of time spent in hypoglycemia (< 2.6 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Duration of glibenclamide treatment
Délai: At the end of treatment assessed up to 15 days

Duration of glibenclamide treatment.

At the end of treatment assessed up to 15 days
Nutritional intakes and growth
Délai: At the end of treatment assessed up to 15 days

Carbohydrate

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Délai: At the end of treatment assessed up to 15 days

lipid

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Délai: At the end of treatment assessed up to 15 days

protein

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Délai: At the end of treatment assessed up to 15 days

mean caloric intake (kcal/kg/day) during treatment

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Délai: At the end of treatment assessed up to 15 days

mean weight gain (g/kg/day)

At the end of treatment assessed up to 15 days
Nutritional intakes and growth
Délai: At 36 week of amenorrhea corrected age

Carbohydrate

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Délai: At 36 week of amenorrhea corrected age

lipid

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Délai: At 36 week of amenorrhea corrected age

protein

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Délai: At 36 week of amenorrhea corrected age

mean caloric intake (kcal/kg/day) during treatment

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Délai: At 36 week of amenorrhea corrected age

mean weight gain ((g/kg/day)

At 36 week of amenorrhea corrected age
Number of children with episode of hypoglycemia
Délai: At 72 hours after first administration

Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia

At 72 hours after first administration
Number of children with episode of hypoglycemia
Délai: At the end of treatment assessed up to 15 days

Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia

At the end of treatment assessed up to 15 days
Type of adverse reactions on glibenclamide
Délai: At 36 week of amenorrhea corrected age

evaluation of the type of adverse reactions identified during the study

At 36 week of amenorrhea corrected age
Number of adverse reactions on glibenclamide
Délai: At 36 week of amenorrhea corrected age

evaluation of number of adverse reactions identified during the study

At 36 week of amenorrhea corrected age
Number of participants with co-morbidity
Délai: At 36 week of amenorrhea corrected age

Neonatal morbidity assessed at 36 WA corrected age: intraventricular haemorrhage, periventricular leukomalacia, retinopathy of premature newborns, haemodynamic disorders, ulcerative necrotising enterocolitis

At 36 week of amenorrhea corrected age
Mortality
Délai: At 36 week of amenorrhea corrected age

Mortality will be assessed

At 36 week of amenorrhea corrected age
Dose adjustment
Délai: At the end of treatment assessed up to 15 days

Number of dose adjustments, to evaluate the easy of use

At the end of treatment assessed up to 15 days
ease of use by caregivers
Délai: At day one of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day one of treatment
ease of use by caregivers
Délai: At day two of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day two of treatment
ease of use by caregivers
Délai: At day three of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day three of treatment
Plasma concentrations of glibenclamide
Délai: At 3 hours after the first administration

Evaluated by the pharmacokinetics study

At 3 hours after the first administration
Plasma concentrations of glibenclamide
Délai: At 6 hours after the first administration

Evaluated by the pharmacokinetics study

At 6 hours after the first administration
Plasma concentrations of glibenclamide
Délai: At 10 hours after the first administration

Evaluated by the pharmacokinetics study

At 10 hours after the first administration
Plasma concentrations of glibenclamide
Délai: At 24 hours after the first administration

Evaluated by the pharmacokinetics study

At 24 hours after the first administration
Plasma concentrations of glibenclamide
Délai: At 24 hours of blood glucose stabilization

Evaluated by the pharmacokinetics study

At 24 hours of blood glucose stabilization

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Jacques BELTRAND, Pr, Assistance Publique - Hôpitaux de Paris
  • Directeur d'études: Michel POLAK, Assistance Publique - Hôpitaux de Paris
  • Directeur d'études: Delphine MITANCHEZ, CHRU de Tours

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 mai 2023

Achèvement primaire (Réel)

30 octobre 2025

Achèvement de l'étude (Réel)

8 janvier 2026

Dates d'inscription aux études

Première soumission

7 décembre 2022

Première soumission répondant aux critères de contrôle qualité

6 janvier 2023

Première publication (Réel)

18 janvier 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

2 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

1 octobre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner